Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 68788-8463

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 68788-8463). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C:\users\ra\desktop\1.jpg (5a5eca60 Figure 01)

A line graph comparing the percentage of patients with systolic blood pressure (SBP) below 140 mmHg against baseline SBP values ranging from 140 to 180 mmHg. Four treatments are shown: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by different symbols and trends indicating efficacy in lowering SBP.*

FDA Label Image

C:\users\ra\desktop\2.jpg (5a5eca60 Figure 02)

A line graph depicting the percentage of patients with diastolic blood pressure (DBP) less than 90 mmHg across various baseline DBP levels (90 to 110 mmHg). It compares four treatments: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The graph shows higher percentages for Valsartan-HCTZ 320/25 mg and lower for placebo.*

FDA Label Image

C:\users\ra\desktop\3.jpg (5a5eca60 Figure 03)

A line chart showing the percentage of subjects with systolic blood pressure (SBP) below 130 mmHg plotted against baseline SBP values ranging from 140 to 180 mmHg. Four data series are displayed comparing Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, illustrating their effects on reducing SBP below 130 mmHg.*

FDA Label Image

C:\users\ra\desktop\4.jpg (5a5eca60 Figure 04)

A line graph depicting the percentage of patients with diastolic blood pressure (DBP) below 80 mmHg on the vertical axis versus baseline DBP in mmHg on the horizontal axis. The graph compares four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, each represented by distinct markers and lines.*

FDA Label Image

C:\users\ra\desktop\5.jpg (5a5eca60 Figure 05)

Chemical structure diagram of the active ingredient valsartan as part of the product valsartan and hydrochlorothiazide.*

FDA Label Image

C:\users\ra\desktop\6.jpg (5a5eca60 Figure 06)

Chemical structure diagram of hydrochlorothiazide, one of the active ingredients in the valsartan and hydrochlorothiazide prescription tablet. The structure shows a chlorinated benzothiadiazine with sulfonamide and sulfone groups.*

FDA Label Image

A Picture Containing Text, Screenshot, Font, Numberdescription Automatically Generated (D09747f0 029e 4090 949b E939948249b5 00)

Packaging label for Valsartan & HCTZ Tablets USP 160 mg/12.5 mg, a film-coated tablet generic for Diovan HCT. The label shows the dosage strength, manufacturer Solco Healthcare LLC, storage warnings, and space for lot and batch numbers. The label also includes bilingual instructions for use in English and Spanish. The labeler is Preferred Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.